MedTrace Logo

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets

NCT00483002 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3719

Last updated 2012-05-11

Study results available
· View outcomes & findings →

Summary

To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg medication for 12 weeks in smokers

Conditions

  • Smoking Cessation

Interventions

DRUG

varenicline

As prescribed by physician in usual clinical practice.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2011-05-31
Completion
2011-05-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00483002 on ClinicalTrials.gov